New updates to leading aCGH data analysis software
Oxford Gene Technology (OGT), The Molecular Genetics Company, is pleased to announce the latest version (4.5.3) of its class-leading CytoSure™ Interpret Software. Complimentary with all CytoSure array purchases, CytoSure Interpret Software is a powerful and easy-to-use package for the analysis of aCGH data, the gold-standard for copy number variation (CNV) detection. Offering an impressive combination of advanced features, including Automatic Aberration Classification, the software allows the choice of standardised or customised user-defined data analysis.
With this latest version, OGT have introduced several innovative new features that further facilitate and standardise the data analysis workflow in order to deliver rapid access to meaningful results. By using information available in online databases such as DECIPHER and settings defined by the user, the Automatic Aberration Classification enables users to configure the software to automatically perform an initial classification of any detected CNV, accelerating analysis and standardising the interpretation process.
CytoSure Interpret Software allows simultaneous access to sample and experiment information across a network, providing the potential for labs on multiple sites to access a central database. In situations where IT infrastructures don’t permit this, the software now provides the additional functionality for exporting sample and experiment information into other databases, further facilitating sharing of case information and aberration calls.
In addition to the free text phenotype field, users are also now able to use Standardised Phenotype (Human Phenotype Ontology - HPO) terms to simplify and normalise the phenotype description process via a HPO Phenotype Selector window.
Dr Ruth Burton, Product Manager for CytoSure said “CytoSure Interpret Software continues to be cited as a decisive factor when purchasing CytoSure arrays and was a major contributor to our recent success in a competitive NHS tender for the supply of oligo-based arrays for cytogenetics research. Our dedicated software development team are continually implementing enhanced features and capabilities in response to new product development and customer feedback, reflecting the overall OGT strategy to provide the most effective and high quality products, services and support.”
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.